WallStSmart

Butterfly Network Inc (BFLY)vsBoston Scientific Corp (BSX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 16995% more annual revenue ($21.07B vs $123.25M). BSX leads profitability with a 16.6% profit margin vs -43.6%. BSX earns a higher WallStSmart Score of 62/100 (C+).

BFLY

Avoid

27

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -2.75

BSX

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 6.7Quality: 6.0
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BFLY.

BSXOvervalued (-9.2%)

Margin of Safety

-9.2%

Fair Value

$39.15

Current Price

$42.75

$3.60 premium

UndervaluedFair: $39.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BFLY2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
51.7%10/10

Revenue surging 51.7% year-over-year

Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

BSX5 strengths · Avg: 8.2/10
Market CapQuality
$60.84B9/10

Large-cap with strong market position

PEG RatioValuation
0.638/10

Growing faster than its price suggests

P/E RatioValuation
17.7x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.2%8/10

Strong operational efficiency at 20.2%

Areas to Watch

BFLY4 concerns · Avg: 3.5/10
Price/BookValuation
9.2x4/10

Trading at 9.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.71B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BSX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

EPS GrowthGrowth
-21.5%2/10

Earnings declined 21.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : BFLY

The strongest argument for BFLY centers on Revenue Growth, Debt/Equity. Revenue growth of 51.7% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.

Bear Case : BFLY

The primary concerns for BFLY are Price/Book, EPS Growth, Market Cap.

Bear Case : BSX

The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.

Key Dynamics to Monitor

BFLY profiles as a hypergrowth stock while BSX is a value play — different risk/reward profiles.

BFLY carries more volatility with a beta of 2.04 — expect wider price swings.

BFLY is growing revenue faster at 51.7% — sustainability is the question.

BSX generates stronger free cash flow (868M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (62/100 vs 27/100), backed by strong 16.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Butterfly Network Inc

HEALTHCARE · MEDICAL DEVICES · USA

Butterfly Network, Inc., a digital health company, develops, manufactures, and markets ultrasound imaging solutions in the United States and internationally. The company is headquartered in Guilford, Connecticut.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?